.jetcityimage/iStock Editorial by means of Getty Images Morgan Stanley has actually selected Eli Lilly (NYSE: LLY) as its leading biopharma choice for 2025 and also measured one more nine names in the space as obese. The expenditure bank pointed out in a keep in mind that it continues to feel “diabesity is actually readied to become.